<DOC>
	<DOCNO>NCT03032614</DOCNO>
	<brief_summary>This phase II clinical trial combination carboplatin , eribulin , Veliparib .</brief_summary>
	<brief_title>Combination Carboplatin , Eribulin Veliparib Stage IV Cancer Patients</brief_title>
	<detailed_description>This Phase II , non-randomized , open-label , Clinical Trial Combination Carboplatin , Eribulin , Veliparib Patients BRCA-related Cancers .</detailed_description>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must archival biopsy specimen ( preferably metastatic disease ) available research test . If suitable biopsy specimen available , patient ask undergo research biopsy procure tissue Patients must &gt; /= 18 year Females childbearing potential must unprotected sexual intercourse within 30 day prior study entry must agree use highly effective method contraception . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior dose must continue use contraceptive study 30 day study drug discontinuation Patients must ECOG performance status 01 Patients may prior diagnosis cancer &gt; 5 year since last treatment cancer Patients must normal organ marrow function define : Leukocytes ≥ 3,000/uL Absolute neutrophil count ≥ 1,500/uL Platelets ≥ 100,000/uL Creatinine within normal limit creatinine clearance ≥30 Patients must able swallow retain oral medication Patients receive prior systemic therapy : Prior treatment related side effect must resolve &lt; Grade 2 severity ( except alopecia infertility ) All patient must give sign , informed consent prior registration study Patients must stage IV breast stage III IV ovarian cancer ( include platinum sensitive disease ) Patients must BRCA1/2 deleterious mutation , PTEN deficiency , cancer high HRD score assess Myriad 's assay Patients must measurable disease per RECIST 1.1 criterion ( see definition ) Patients may receive 3 chemotherapeutic regimen metastatic disease Patients may receive treatment prior carboplatin , eribulin PARP inhibitor Women pregnant lactate eligible Patients undergo concomitant radiotherapy eligible Patients receive investigational agent concurrent anticancer therapy eligible Previous systemic treatment allow 21 day washout period prior registration Patients take herbal ( alternative ) medicine eligible . Patients must medications time registration Patients know brain metastasis eligible participation unless follow met : Brain metastasis treat ( either surgical excision , stereotactic radiosurgery radiotherapy stable least 4 week ( MRI document ) Patient asymptomatic discontinue corticosteroid take purpose Patients follow condition complication NOT eligible participation : GI tract disease result inability take oral medication Malabsorption syndrome Require IV alimentation History prior surgical procedure affect absorption Uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . Hypersensitivity component Veliparib , carboplatin , eribulin History significant neurological ( neuropathy &gt; Grade 2 ) psychiatric disorder . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis ) . Significant nonneoplastic renal disease . Immunocompromised subject , include subject know infected human immunodeficiency virus ( HIV ) . Uncontrolled endocrine disease ( e.g. , diabetes mellitus , hypothyroidism hyperthyroidism , adrenal disorder ) i.e. , require relevant change medication within last month hospital admission within last three month Active infection require systemic therapy . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II , uncontrolled arterial hypertension , unstable angina , myocardial infarction stroke within 6 month first dose study drug ; cardiac arrhythmia require medical treatment . Prolongation QTc interval &gt; 480 msec electrolyte balance normal . Major surgery within 4 week prior first dose study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>